# Immunovant (IMVT) — News

IMVT · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/imvt/news

## Recent headlines

- [Immunovant shares down 2% after co to stop development of imvt-1402 in Cle](https://www.ainvest.com/news/immunovant-shares-2-stop-development-imvt-1402-cle-2609) — AInvest Wire, Sep 23, 2026
- [Immunovant shares down 6.7% premarket after co to stop development of imvt-1402 in Cle](https://www.ainvest.com/news/immunovant-shares-6-7-premarket-stop-development-imvt-1402-cle-2609) — AInvest Wire, Sep 23, 2026
  Immunovant Inc. (IMVT) shares fell 6.7% in premarket trading on September 23, 2026, following the company’s announcement that it will discontinue the development of its drug candidate IMVT-1402 in the Cleveland (Cle) region. The decision marks a strategic shift for the biopharmaceutical firm, which…
- [Immunovant: All other clinical development timelines remain on track](https://www.ainvest.com/news/immunovant-clinical-development-timelines-remain-track-2609) — AInvest Wire, Sep 23, 2026
- [Immunovant, - IMVT-1402 demonstrates favorable safety and tolerability profile](https://www.ainvest.com/news/immunovant-imvt-1402-demonstrates-favorable-safety-tolerability-profile-2609) — AInvest Wire, Sep 23, 2026
- [Immunovant, - IMVT-1402 study in Cle did not achieve statistical significance on primary endpoint](https://www.ainvest.com/news/immunovant-imvt-1402-study-cle-achieve-statistical-significance-primary-endpoint-2609) — AInvest Wire, Sep 23, 2026

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).